BioAtla (BCAB) Research & Development (2020 - 2026)

BioAtla's Research & Development history runs 7 years deep, the most recent figure standing at $4.6 million for Q1 2026.

• On a quarterly basis, Research & Development fell 62.91% year-over-year to $4.6 million in Q1 2026; TTM through Mar 2026 was $35.8 million, a 36.75% decrease from a year earlier, with the FY2025 full-year figure at $43.6 million, down 30.94% from the prior year.
• Research & Development slipped to $4.6 million in Q1 2026 per BCAB's latest filing, from $8.0 million in the prior quarter.
• Across five years, Research & Development topped out at $31.0 million in Q2 2023 and bottomed at $4.6 million in Q1 2026.
• The 5-year median for Research & Development is $16.9 million (2022), against an average of $17.3 million.
• Across the five-year window, Research & Development soared 62.36% in 2022 and plunged 62.91% in 2026, its largest moves.
• Year by year, Research & Development stood at $21.9 million in 2022, then climbed by 3.66% to $22.7 million in 2023, then sank by 48.62% to $11.6 million in 2024, then tumbled by 31.37% to $8.0 million in 2025, then slumped by 42.69% to $4.6 million in 2026.
• Per Business Quant, the three latest BCAB Research & Development figures stand at $4.6 million (Q1 2026), $8.0 million (Q4 2025), and $9.5 million (Q3 2025).